Pharmaceutical United Biotechnology Co., Ltd. (WUXI XDC) announced its annual results for the year ended December 31, 2023, with revenues up 114.4% year-on-year to RMB2,123.8 million, gross profit year-on-year up 114.3% to RMB559.6 million, and adjusted net profit growth of 112.1% to RMB559.6 million by company owners RMB 412.3 million. The company successfully completed its global IPO in November 2023 and was listed on the exchange's main boards with a total of over HK$40 billion. The Company provides comprehensive CRDMO services, including discovery, process development and GMP production of biodulated drugs, monoclonal antibody intermediates and biodominant drug-related ligands and payloads. The company will further expand its service capacity and capabilities in the future and plans to build facilities at its Singapore base to meet growing global demand.

Pharmaceutical United Biotechnology Co., Ltd. (WUXI XDC) announced its annual results for the year ended December 31, 2023, with revenues up 114.4% year-on-year to RMB2,123.8 million, gross profit year-on-year up 114.3% to RMB559.6 million, and adjusted net profit growth of 112.1% to RMB559.6 million by company owners RMB 412.3 million. The company successfully completed its global IPO in November 2023 and was listed on the exchange's main boards with a total of over HK$40 billion. The Company provides comprehensive CRDMO services, including discovery, process development and GMP production of biodulated drugs, monoclonal antibody intermediates and biodominant drug-related ligands and payloads. The company will further expand its service capacity and capabilities in the future and plans to build facilities at its Singapore base to meet growing global demand.